BASINGSTOKE, England, June 21 /PRNewswire-FirstCall/ -- Shire plc held its Annual General Meeting today. All resolutions were put to the meeting and approved on a show of hands. The proxy votes received for the meeting are set out below:
For* Against Abstentions** 1. To receive and consider the directors’ report 359,071,857 675,088 1,574,434 and accounts for the year ended 31 (99.81%) (0.19%) December 2005 2. To re-elect Dr James 360,237,140 617,865 Henry Cavanaugh as a director (99.83%) (0.17%) 466,374 3. To re-elect Mr Robin 360,460,134 403,668 William Turnbull Buchanan as a (99.89%) (0.11%) 457,577 director 4. To re-elect Mr 358,012,655 1,004,977 Matthew William Emmens as a director (99.72%) (0.28%) 2,303,747 5. To re-elect the 357,125,147 2,752,824 Honourable James Andrews Grant as a (99.24%) (0.76%) 1,443,408 director 6. To re-elect Mr David 358,720,911 2,140,994 John Kappler as a director (99.41%) (0.59%) 459,474 7. To elect Mr Patrick 360,310,235 551,670 Jean Mark Langlois as a director (99.85%) (0.15%) 459,474 8. To re-elect Mr 355,747,898 552,524 Ronald Maurice Nordmann as a (99.84%) (0.16%) 5,020,957 director 9. To re-elect Dr Barry 354,069,599 2,231,923 John Price as a director (99.37%) (0.63%) 5,019,857 10. To re-elect Mr Angus 358,109,095 916,203 Charles Russell as a director (99.74%) (0.26%) 2,296,081 11. To re-appoint 350,604,574 6,521,791 Deloitte & Touch LLP as Auditors (98.17%) (1.83%) 4,195,014 12. To authorise the 359,770,712 1,187,866 Audit Committee to determine the (99.67%) (0.33%) 362,801 remuneration of the Auditors 13. To approve the 339,634,086 11,273,314 Directors’ Remuneration Report (96.79%) (3.21%) 10,413,979 14. To authorise the 355,037,733 6,159,314 allotment of shares (98.29%) (1.71%) 124,332 15. To authorise the 358,499,820 2,669,655 disapplication of pre-emption rights (99.26%) (0.74%) 152,904 16. To authorise market 361,026,133 238,054 purchases (99.93%) (0.07%) 57,192 17. To authorise 354,116,165 5,286,233 donations to EU political (98.53%) (1.47%) 1,918,981 organisations and EU political expenditure * These figures include discretionary votes
** Abstentions are not counted in the proportion of votes “for” or “against”
Notes to Editors
Shire plc
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com
Shire plc
CONTACT: For further information please contact: Investor Relations, CleaRosenfeld (Rest of the World), +44-1256-894-160. Brian Piper (NorthAmerica), +1-484-595-8252
